FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.

What a map of Queensland reveals about health inequality

Researchers have used geospatial data to illustrate significant life expectancy differences across Queensland, including for areas only kilometers apart within cities. Health geographer Associate Professor Jonathan Olsen ...

page 1 from 10